

Genetic and epidemiological risk factors in the development of bronchopulmonary dysplasia

Beena Mailaparambil¹, Marcus Krueger¹, Ulrike Heizmann, Katharina Schlegel, Jessica Heinze and Andrea Heinzmann*

Centre for Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany

Abstract. Bronchopulmonary dysplasia (BPD) is the chronic lung disease of preterm infants and still represents a major burden of prematurity. Several clinical risk factors for the onset of the disease are already known. In addition, some candidate genes have recently been identified. We set out to determine clinical as well as genetic risk factors for the development of BPD in the German population.

155 infants born with a gestational age ≤ 28 at the tertiary neonatal Centre, Freiburg, were recruited. Clinical data were recorded from hospital charts. 47 children developed moderate or severe BPD. For genetic analyses, 37 polymorphisms within sixteen genes were genotyped on all children.

The strongest epidemiological risk factor for BPD was birth weight, followed by low gestational age. Genetic association was detected with single polymorphisms within *Tumour necrosis factor alpha*, *Toll like receptor 10* and *vascular endothelial growth factor*. The former two genes showed also association with BPD in haplotype analyses.

In conclusion, association of BPD was far more convincingly found with a few clinical factors than with genetic polymorphisms. This underscores the genetic complexity of the disease. Furthermore, the identification of predisposing genetic polymorphisms might be hampered by the complex interaction between clinical and genetic factors.

Keywords: Association, bronchopulmonary dysplasia, genetic, polymorphism

1. Introduction

Bronchopulmonary dysplasia (BPD) is the chronic lung disease of premature infants; it affects about 20–30% of children born at a gestational age of less than 30 weeks. The disease is primarily characterised by a prolonged need of oxygen supplementation. However, affected children are also more likely to develop sequelae like language delay, cerebral palsy, and cognitive impairments [1]. Thus BPD is still the leading cause of morbidity and mortality among premature infants [2, 3].

BPD was first described and characterised by Northway et al. in 1967 [4]. Since then, a variety of different definitions have been published and used in clinical practice. Most widely applied was the definition of the NIH workshop on BPD in 1979, which postulated at least 28 days of supplemental oxygen in addition to radiographic changes [5]. Lately, improved therapeutically options – especially advanced technology for mechanical ventilation – and the survival of even smaller infants have changed the clinical appearance of BPD. This led to the advent and classification of the so-called “new BPD” [6]: Now oxygen supplementation for at least 28 days and at 36 weeks postmenstrual age as well as the need of positive airway pressure categorize the severity of the disease in mild, moderate and severe [7, 8].

At least two important pathophysiological pathways exist in the development of the new BPD: First, inflam-

¹These two authors contributed equally to this work.

*Corresponding author: Dr. Andrea Heinzmann, Centre for Pediatrics and Adolescent Medicine, Mathildenstr. 1, D-79106 Freiburg, Germany. Tel.: +49 761 2706371; Fax: +49 761 2706372; E-mail: andrea.heinzmann@uniklinik-freiburg.de.

matory processes that lead to an impairment of alveolarization and vasculogenesis and secondly, growth arrest of the lungs [9,10]. The primary event might already occur *in utero* by inflammation due to chorioamnionitis or immediately postnatal by lung injury due to respiratory distress syndrome and its treatment by mechanical ventilation. The persistence of this inflammation – mediated by influx of neutrophils and macrophages in the airways followed by production of reactive oxygen species – finally contributes to impaired lung development, ultimately resulting in BPD [11].

It has been hypothesised already years ago, that in addition to clinical factors a genetic predisposition might determine the development of BPD [12,13]. This hypothesis is supported by recent twin studies, suggesting that genetic factors contribute as much as 53% to the total risk for the disease [13,14].

Therefore we were interested to identify risk factors for the development of BPD in the German population taking into account both – clinical and genetic – factors. Besides recording and analysing clinical characteristics of the study population, we genotyped 37 polymorphisms within sixteen candidate genes for BPD: These are genes for the airway mucosal response like surfactant protein C and surfactant protein D (SFPC and SFPD); different growth factors involved in lung remodelling: transforming growth factor (TGF) alpha and beta, connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF). Extracellular matrix and adhesion -molecules (such as metalloproteinases) have already been analyzed for their involvement in BPD [15]. Therefore we included in our analysis selectin E (SELE) and intercellular adhesion molecule (ICAM-1) as our study group analyzed these factors previously in other pediatric diseases [16–18]. Finally genes involved in inflammation and innate immune response: Interleukin (IL-)-13, IL-4, IL-8, IL-10, IL-18, tumour necrosis factor (TNF) alpha and beta and toll like receptor (TLR-) 10 were analyzed. The selection of SNPs was based on previous studies of the genes by others as well as by us [19].

2. Material and methods

2.1. Subjects

Preterm infants (gestational age \leq 28) born between January 1996 and August 2007 at the Centre for Pediatrics and Adolescent Medicine, University Hospital Freiburg, Germany, were included: Infants were re-

cruited prospectively during their stay on NICU since January 2005. Children born before that time were recruited retrospectively by contacting the parents by mail.

DNA collection was performed either by buccal swabs (majority of cases) or by blood drawing in case of routine blood sampling. Children with chromosomal aberrations, congenital heart defects or other major congenital malformations were excluded from the study. All probands were genetically independent, i.e. no twins or siblings were included. Furthermore, only Caucasian children were recruited for the study to guarantee a homogenous ethnic background of the study population.

Medical charts of the infants were reviewed and clinical data recorded. This included among others the following parameters: Sex, birth weight, gestational age, number of days with supplemental oxygen, need of mechanical ventilation and positive airway pressure, patent ductus arteriosus (as confirmed echographically) and mode of closure (i.e. pharmaceutical or surgical), chorioamnionitis according to placenta histology (hematoxylin and eosin stain), sign of early onset neonatal infection (like elevated C reactive protein and/or IL-6 in cord blood), need of surfactant therapy and courses of prenatal steroids. At our NICU the following approach is applied regarding the treatment with surfactant: Avoiding of intubation independent of the gestational age. Therefore, even very premature infants are only intubated if they show failure of ventilation and/or need of supplemental oxygen above 40%. Once they required intubation during the immediate postnatal period, they receive surfactant within 2 hours. This practice was consistent during the whole study period.

The BPD definition by Jobe and Bancalari [6] was used to subdivide the infants in two groups. Group 1 included all infants with no or only mild BPD, corresponding to oxygen supplementation for at least 28 days, but no need of supplemental oxygen or positive pressure at 36 weeks of gestational age. Group 2 consists of all infants with moderate and severe BPD (BPD grade two and three according to the original definition), i.e. supplemental oxygen for at least 28 days plus need of oxygen and/or positive pressure at 36 weeks of gestational age. This classification is based on the recent analyses by Lavoie et al. about the heritability of BPD as defined according to the consensus statement of the national institutes of health [20].

2.2. Genotyping

DNA was extracted by standard procedures from peripheral blood leucocytes and column purified (DNA

Table 1
RFLP analyses

Gene	SNP	Primers	PCR condition	Restriction enzyme
TNF α	rs1799964	5' GGGGAGAACAAAAGGATAAG 3' 5' CCCCATACTCGACTTTTCATA 3'	55°C, 40 cycles	MaeIII
	rs1799724	5' GTATGGGGACCCCCCGTAA 3' 5' GACCCGGAGACTCATAATGC 3'	65°C, 35 cycles	MaeIII
	rs1800629	5' AGGCAATAGGTTTTGAGGGCCAT 3' 5' GAGCGTCTGCTGGGTGGTG 3'	55°C, 40 cycles	NcoI
TNF β	rs909253	5' CCGTGCTTCGTGCTTTGGACTA 3' 5' AGAGCTGGTGGGGACATGTCTG 3'	69°C, 35 cycles	NcoI
VEGF	rs699947	5' AACCTAGCACCTCCACCAAAA 3' 5' GAACAAAGTTGGGGCTCTGA 3'	56°C, 35 cycles	BglIII
	rs2010963	5' GCCATTCCCCACTTGAAT 3' 5' GTCACCTACTTTGCCCTGT 3'	56°C, 35 cycles	HypF10VI
	rs3025039	5' ACACCATCACCATCGACAGA 3' 5' GCTCGGTGATTAGCAGCA 3'	56°C, 35 cycles	HinIII
TLR-10	rs4274855	5' TCCTGACTTACCTCAACAcC 3' 5' AAGTCTGCGGGAACCTTTCT 3'	59°C, 35 cycles	MspI
	rs11096955	5'GGTAAGGCTTATCTTGACCACA3' 5' GACGAGTTGTTTAAAAGGACT 3'	54°C, 35 cycles	Hinf I
	rs10856839	5'CATCATTCATATGAGGAATT 3' 5' AAGTCTGCGGGAACCTTTCT 3'	52°C, 40 cycles	MseI

Primers, PCR condition and restriction enzymes for performing RFLP. Shown is the condition for all SNPs in genes with significant results.

Table 2
Some characteristics of the study population

	No BPD/mild BPD ($n = 108$)	Moderate/severe BPD ($n = 47$)
Gestational week*	26 (23–28)	25 (23–28)
Sex (proportion males)	0.454	0.532
Birth weight [g]*	905 (450–1500)	690 (350–1020)
Prenatal steroids		
– incomplete	14 (13.0%)	10 (21.2%)
– complete	85 (78.7%)	34 (72.3%)
Surfactant therapy	41 (38%)	33 (70.2%)
Chorioamnionitis	48 (44.4%)	20 (42.5%)
PDA, closure by		
– pharmacological	32 (29.6%)	14 (29.8%)
– surgical intervention	5 (4.6%)	13 (27.7%)

This table shows some clinical characteristics of the two groups of preterm infants. * median and range.

midikit, Qiagen, Hildesheim, Germany). In case of buccal swabs the GenomiPhi V2 DNA amplification kit (GE Healthcare, Munich, Germany) was used.

Genotyping was performed by restriction fragment length polymorphism (RFLP) as described previously [19]. The conditions for RFLP analyses for all SNPs within genes showing significant results – i.e. *TNF alpha* and *beta*, *VEGF* and *TLR10* – are shown in Table 1.

2.3. Sequencing

In order to check the accuracy of RFLP analyses, for each polymorphism three controls (homozy-

gous wildtype, heterozygous and homozygous mutation) were sequenced by the dideoxy chain termination method [21] using the Big Dye Terminator cycle sequencing kit on an ABI 310 sequencer (Applied Biosystems). All subsequent RFLP analyses included these reference individuals.

2.4. Statistical analysis

Clinical data were analysed by using the SPSS 11.0 package (SPSS Inc., Chicago, Illinois, USA). Genotyping data were analysed for possible association with BPD by using the Armitage's trend

test for each single polymorphism. This test follows the guidelines given by Sasieni [22] and is implemented in the program Finetti (Thomas F. Wienker, unpublished data; <http://ihg.gsf.de/cgi-bin/hw/hwa1.pl> and <http://ihg.gsf.de/linkage/download/finetti.zip>). The same program was used to calculate Hardy Weinberg equilibrium (HWE) for each polymorphism in both populations. A significant deviation from HWE could be a hint to population admixture or genotyping errors [23]. In addition, we performed haplotype frequency estimations and association analyses with FAMHAP [24].

2.5. Approval

The collection of blood/buccal swabs and the experimental procedures were approved by the Ethical Committee of the University of Freiburg. Parents were given written and verbal information about the study and a statement of informed consent was signed by the parents of all enrolled children.

3. Results

3.1. Clinical characteristics – epidemiological risk factors

Initially all infants born at a gestational age ≤ 32 were recruited for our study. However, as BPD was diagnosed only 3 times in 60 infants born between a gestational age of 29 and 32 weeks, these children were eventually excluded from further analyses. Thus 155 children born ≤ 28 weeks of gestational age were included and divided in two groups: 108 infants were assigned to group 1 (no or only mild BPD); 47 infants met inclusion criteria for group 2 (moderate or severe BPD). Some baseline characteristics of both groups are shown in Table 2.

The following major clinical risk factors for BPD were present in our population: Low birth weight was associated with BPD with a χ^2 of 49.6 ($p < 0.000001$ by Kruskal-Wallis-Test) and low gestational age with $\chi^2 = 40.0$ ($p < 0.000001$ by Kruskal-Wallis-Test). In addition, length of mechanical ventilation was very strongly associated with the development of BPD ($\chi^2 = 61.1$, $p < 0.000001$ by Kruskal-Wallis-Test). The relationship of low birth weight and length of mechanical ventilation with BPD severity is illustrated in Fig. 1a and b.

Table 3
Polymorphisms under investigation

Gene	Polymorphism	Alleles	Position
IL-8	rs4073	A/T	Promoter
	rs227306	C/T	Intron
SFTPC	rs8192341	A/C	T138N
	rs1124	A/G	S186N
SFTPD	rs3088308	A/T	S290T
	rs721917	C/T	M31T
TNF α	rs1799964	C/T	5' UTR
	rs1799724	C/T	5' UTR
	rs1800629	A/G	Promoter
TNF β	rs909253	C/T	Intron
IL-4	rs2243250	C/T	Promoter
IL-13	rs1881457	A/C	Promoter
	rs1800925	C/T	Promoter
	rs20541	C/T	Q144R
VEGF	rs699947	A/C	Promoter
	rs2010963	C/G	5' UTR
	rs3025039	C/T	3' UTR
TGF β	rs1800471	C/G	5' UTR
	rs1800469	C/T	5' UTR
TGF α	rs2166975	A/G	V160V
IL-10	rs3024498	A/G	3' UTR
	rs1800872	A/C	Promoter
SELE	rs5368	C/T	H468Y
	rs5361	A/C	S149R
CTGF	rs9399005	C/T	5' UTR
	rs6918698	C/G	Promoter
ICAM	rs5498	A/G	Promoter
	rs885743	A/T	Intron
IL-18	rs1946518	G/T	Promotor
	rs187238	C/G	Promotor
	rs360718	A/C	Exon
	rs360717	C/T	Exon
	rs795467	A/G	Intron
TLR10	rs360721	C/G	Intron
	rs4274855	C/T	Promotor
	rs11096955	A/C	I369L
	rs10856839	A/C	5' UTR

SNPs under investigation and their position within the genes. The corresponding nucleotide substitution is shown as well as the amino acid exchange where applicable.

BPD was more often seen in infants who had a patent ductus arteriosus (PDA) with need of either pharmaceutical or surgical therapy. Highest incidence of BPD was seen in infants undergoing surgical ligation of PDA ($p < 0.0001$, Kruskal-Wallis-Test). Finally, boys were not more often affected than girls in our study ($p = 0.419$ by Kruskal-Wallis-Test).

3.2. Association analyses – genetic risk factors

155 infants were genotyped for 37 single nucleotide polymorphisms (SNPs) within 16 genes. The genes and SNPs under investigation are listed in Table 3. The genotyping data, the results of HWE calculation and p-values for association with BPD as calculated by the Armitage's Trend test are shown in Table 4.




Fig. 1. BPD severity as defined by Bancalari et al. [6]. Shown are the median and the 95% confidence interval. Small circles represent outlier. a) According to birth weight. b) According to days of mechanical ventilation.

Table 4
Results of association analyses

Gene	Polymorphism	Genotypes BPD	HWE BPD	Genotypes controls	HWE controls	<i>p</i> value for association
IL-8	rs227306	11,28,7	0.124	27,57,22	0.423	0.7333
	rs4073	8,30,7	0.025	22,60,25	0.206	0.6578
SPC	rs8192341	24,17,4	0.714	60,37,8	0.498	0.6560
	rs1124	18,26,2	0.092	47,48,9	0.506	0.8717
SPD	rs721917	20,16,10	0.067	32,57,17	0.316	0.5404
	rs3088308	40,5,1	0.218	90,14,3	0.044	0.6576
TNF α	rs1799724	33,6,5	0.002	93,15,0	1.000	0.0085
	rs1799964	25,19,0	0.170	69,36,2	0.356	0.5290
	rs1800629	33,10,1	0.579	75,28,4	0.490	0.5037
TNF β	rs909253	20,19,4	1.000	54,40,12	0.281	0.8427
IL-4	rs2243250	33,12,0	1.000	83,21,3	0.366	0.8665
IL-13	rs1881457	25,19,1	0.408	70,31,6	0.362	0.5292
	rs1800925	30,13,2	0.637	71,32,5	0.544	0.9130
VEGF	rs20541	28,14,1	1.000	68,34,4	1.000	0.8090
	rs2010963	27,15,5	0.258	50,43,15	0.252	0.2393
	rs699947	9,19,18	0.339	31,57,19	0.414	0.0138
TGF β	rs3025039	37,8,1	0.421	85,23,0	0.603	0.9529
	rs1800471	37,7,0	1.000	96,7,2	0.021	0.4069
	rs1800469	14,26,5	0.172	41,50,17	0.787	0.8530
TGF α	rs2166975	26,16,4	0.464	57,44,7	0.700	0.8896
IL-10	rs1800872	23,17,5	0.490	61,34,10	0.118	0.4725
	rs3024498	24,19,2	0.699	68,30,8	0.089	0.4822
SELE	rs5361	34,12,0	1.000	87,20,0	0.594	0.3024
	rs5368	35,12,0	1.000	84,20,4	0.074	0.9635
CTGF	rs6918698	10,19,17	0.295	39,38,30	0.003	0.0906
	rs9399005	31,15,0	0.580	65,32,10	0.053	0.1396
ICAM	rs885743	20,12,8	0.037	34,50,18	0.959	0.2894
	rs5498	23,14,7	0.056	41,51,14	0.765	0.3829
IL18	rs1946518	10,25,9	0.363	40,54,13	0.420	0.0539
	rs187238	23,14,8	0.048	60,31,16	0.002	0.5557
	rs360718	26,15,3	0.683	60,44,3	0.125	0.9225
	rs360717	25,16,4	0.701	59,44,4	0.223	0.6548
	rs795467	24,17,3	1.000	59,42,5	0.470	0.7640
TLR10	rs360721	31,14,1	1.000	73,28,4	0.497	0.9585
	rs10856839	27,9,3	0.118	74,26,3	0.706	0.4771
	rs11096955	23,16,5	0.468	30,59,18	0.227	0.0149
	rs4274855	31,10,3	0.125	59,40,8	0.736	0.1559

This table summarizes the results of genotyping. Given are the genotype distribution – as numbers of individuals for each genotype – in the BPD group (moderate and severe BPD) and controls (i.e. no or mild BPD), the *p* values for Hardy-Weinberg-Equilibrium (HWE) and the *p*-values for association with BPD.

Association of BPD was detected with three SNPs within three different genes: rs1799724 in *TNF-alpha* ($p = 0.0085$), rs699947 in *VEGF* ($p = 0.0138$) and rs11096955 in *TLR10* ($p = 0.0149$). However, one should bear in mind that by applying Bonferroni correction for all tested SNPs the association does not stay significant.

Furthermore, haplotype analysis was performed by FAMHAP for those genes in which at least two SNPs were genotyped. Genes lying next to each other on the same chromosomes were combined in analyses – these are *IL-4* and *IL-13* as well as *TNF-alpha* and – *beta*. The results are demonstrated in Table 5. Weak association of BPD was found with haplotypes of *TNF alpha/beta* ($p = 0.0544$) and *TLR10* ($p = 0.0273$).

4. Discussion

In this study we sought to identify epidemiological and genetic risk factors for the development of the chronic lung disease of prematurity, bronchopulmonary dysplasia. In our study population, 47 out of 155 infants born at a gestational age of ≤ 28 weeks developed moderate or severe BPD.

The major clinical risk factors for BPD in this population were low birth weight, low gestational age and a long period of mechanical ventilation (see also Fig. 1). In the modern concepts of testing infants of extreme low birth weight exposed to more gentle procedures for mechanical ventilation, the impact of barotrauma and oxygen toxicity has decreased and low birth weight and

young gestational age have become even more important. Additional strong risk factors for the so-called new BPD include early infection – either prenatal or nosocomial – and a PDA [25]. Accordingly, we found strong association with the mode of PDA closure and BPD. In infants undergoing surgical ligation of PDA the prevalence of BPD was highest. However, it is not possible to decide on the basis of our results whether primarily the ductus arteriosus remains open due to lung disease or whether BPD develops due to persisting ductus and the consecutive blood flooding of the lung. While these risk factors are already known and well described [26,27] nowadays genetic factors come in the focus of interest.

During the last years, a few candidate genes studies have been published in the context of BPD. The inclusion criteria of the study populations varied greatly between different research groups; this might explain some of the conflicting results. For example, some studies used healthy term infants as controls to preterm infants with BPD [28]. The results of such studies might be biased to the identification of genes for prematurity rather than genes for BPD. Others included all preterm infants (i.e. born \leq 36 weeks of gestational age); as BPD develops only very rarely in infants born at a gestational age \geq 30 weeks this might also hamper the identification of true association.

To overcome these forms of bias as much as possible we included only children born \leq 28 weeks of gestational age. This group was divided in BPD affected children and controls according to the definition by Jobe et al. [6]. In addition, only children with need of supplemental oxygen and/or positive airway pressure at a gestational age of 36 weeks were included in the case population, i.e. moderate and severe BPD. This classification was chosen for three reasons: First, the case number of this study population would be too small to subdivide the infants into four groups according to disease severity (no, mild, moderate, severe BPD). Secondly, infants with mild BPD were combined to children without BPD as for very premature infants – as represented in our study population – oxygen supplementation for 28 days might rather reflect a normal transiently condition than lung disease. Thus only oxygen supplementation at a gestational age of 36 weeks (or positive airway pressure) qualified for the case population. Thirdly, this classification is supported by a recent study by Lavioe and colleagues [20]: By investigating 318 twin pairs of known zygosity, they identified genetic factors to account for 82% of the observed variance in BPD susceptibility as defined on the basis of need for supplemental oxygen at 36 weeks of gestational age.

Table 5
Results of haplotype analyses

Gene	p
Interleukin-8	0.2546
Surfactant Protein C	0.4284
Surfactant Protein D	0.5605
Tumour necrosis factor alpha and beta	0.0544
Interleukin-4/-13	0.6270
Vascular endothelial growth factor	0.2521
Transforming growth factor beta	0.6523
Interleukin-10	0.5096
Selectin E	0.6232
Connective tissue growth factor	0.2908
Intercellular adhesion molecule 1	0.4373
Interleukin-18	0.6430
Toll like receptor 10	0.0273

This table shows the results of haplotype analyses using the program FAMHAP.

Heritability of BPD is based on different processes influencing the premature lung during its development. The inflammatory process which may already start prenatal is one of the targets for genetic research. It is well known that inflammatory activation of different cell types such as macrophages, lymphocytes or neutrophils trigger the development of BPD. The pathways including activation and control of the lung response to injury is represented in this study by the analysis of polymorphisms in different interleukins and TNF genes. Using this approach, association was identified with polymorphisms of *TNF alpha*, *VEGF* and *TRL10* and BPD.

TNF-alpha plays a major role in the regulation of inflammation by affecting the release of other pro-inflammatory cytokines. Polymorphisms may lead to prolonged inflammation and consecutively tissue damage. Exaggerated reparative procedures of the immature lung may as well enhance lung injury such as fibrosis. Association of *TNF alpha* with BPD has already been described some years ago [29]. However, other failed to replicate these findings [30]; this might be caused by the smaller sample size. Just very recently, association of *TNF alpha* haplotypes was described with levels of TNF alpha in tracheal aspirate fluids of preterm infants. Furthermore, the authors found association of haplotypes with the occurrence of chorioamnionitis, but not with BPD [31]. In our study population, association of the polymorphism rs1799724 and TNF alpha haplotypes with BPD was only weak and does not hold up Bonferroni correction. Still, the same SNP was found to alter gene expression [32]. Furthermore, we recently demonstrated that this polymorphism is in association with altered serum levels of TNF-alpha in an asthmatic population [33]. Taken to-

gether with the above mentioned studies genetic variants in TNF alpha may only play a minor (and thus sometimes elusive) role in the genetic predisposition to BPD. Interestingly, this has just been confirmed very recently in a meta-analysis [34].

The involvement of VEGF particularly in the pathophysiology of new BPD was reviewed recently [35]. By the definition of new BPD as arrest of lung development rather than lung injury, genetic factors involved in the development of vessels and bronchial branching came into the focus of genetic analysis. VEGF represent a vital factor in endothelial differentiation and angiogenesis. Absence of VEGF results in impaired formation of the micro-vascular architecture [36,37]. Relevant implications of VEGF polymorphisms were described in different studies, for example altered VEGF serum levels [38,39]. We found association of rs699947 in *VEGF* with BPD ($p = 0.0138$). Also association of *VEGF* with BPD has been described in the Polish population just some months ago [40]. Kwinta et al. used different SNPs within *VEGF* than we used in our own study. Identification of association with different SNPs in *VEGF* might underscore the importance of this gene in BPD development.

Until now, no data have been published about the role of TLR10 in the pathophysiology of BPD. However, as TLR10 is part of the innate immune response and infections are an important risk factor for BPD an involvement seems reasonable. The association of one single polymorphism was also supported by haplotype association in our population. In addition, TLR10 have already been described in association with other lung diseases like bronchial asthma [41]. However, once again this association is not robust to correction for multiple testing and thus it might be possible, that the association is false positive.

The other thirteen genes under investigation did not show any hint for an involvement in the genetic predisposition to BPD. Even IL-13 and IL-4 as very strong inflammatory cytokines did not show any association. A previous study in Taiwanese children also failed to find association of IL-4 with the disease [42]. SNPs tested in different surfactant proteins were shown to be associated with BPD in the surfactant protein-C and -D genes, although different SNPs were compared between these two studies [43].

However, the case number of our study is still limited and thus some genes might escape significance for association due to a limited statistical power. As prematurity beyond a gestational age of 28 weeks is quite rare, sufficient case numbers and thus statistical power

might only be reached by a multi-centre approach. However, combining children born in different clinics may also confer potential bias, as postnatal treatment varies between centres.

We conclude that even using the options of advanced neonatal treatment the established clinical risk factors still show a high impact on the development of BPD. In addition, our results point to an involvement of immune- and angiogenesis-related genes in the genetics of BPD. Still, the candidate genes identified in this single-centre study need confirmation in larger study populations.

Acknowledgements

We wish to thank all the infants and their families for their willingness to join our study. In addition, we like to express our thanks to the team of the Neonatal intensive care Unit for supporting the study.

References

- [1] M.C. Walsh, S. Szefer, J. Davis, M. Allen, L. Van Marter, S. Abman, L. Blackmon and A. Jobe, Summary proceedings from the bronchopulmonary dysplasia group, *Pediatrics* **117** (2006), 52–56.
- [2] J.P. Kinsella, A. Greenough and S.H. Abman, Bronchopulmonary dysplasia, *Lancet* **367** (2006), 1421–1431.
- [3] G. Bokodi, A. Treszl, L. Kovács, T. Tulassay, B. Vásárhelyi, Dysplasia, a review, *Pediatr Pulmonol* **42** (2007), 952–961.
- [4] W.H. Jr. Northway, R.C. Rosan and D.Y. Porter, Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia, *N Engl J Med* **276** (1967), 357–368.
- [5] Report of workshop on Bronchopulmonary dysplasia; NIH publication No. 80–1660. Washington, DC, National Institutes of Health; 1979.
- [6] A.H. Jobe, E. Bancalari, Bronchopulmonary dysplasia, *Am J Respir Crit Care Med* **163** (2001), 1723–1729.
- [7] R.A. Ehrenkranz, M.C. Walsh, B.R. Vohr, A.H. Jobe, L.L. Wright, A.A. Fanaroff, L.A. Wraage and K. Poole, National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia, *Pediatrics* **116** (2005), 1353–1360.
- [8] R.M. Ryan, A new look at bronchopulmonary dysplasia classification, *J Perinatol* **26** (2006), 207–209.
- [9] C.T. D'Angio and W.M. Maniscalco, The role of vascular growth factors in hyperoxia-induced injury to the developing lung, *Front Biosci* **7** (2002), 1609–1623.
- [10] F. Groenman, S. Unger and M. Post, The molecular basis for abnormal human lung development, *Biol Neonate* **87** (2005), 164–177.
- [11] R.M. Ryan, Q. Ahmed and S. Lakshminrusimha, Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia, *Clin Rev Allergy Immunol* **34** (2008), 174–190.

- [12] L.A. Parton, S.S. Strassberg, D. Qian, P.A. Galvin-Parton and I.A. Cristea, The genetic basis for bronchopulmonary dysplasia, *Front Biosci* **11** (2006), 1854–1860.
- [13] V. Bhandari, M.J. Bizzarro, A. Shetty, X. Zhong, G.P. Page, H. Zhang, L.R. Ment and J.R. Gruen, Neonatal Genetics Study Group. Familial and genetic susceptibility to major neonatal morbidities in preterm twins, *Pediatrics* **117** (2006), 1901–1906.
- [14] V. Bhandari and J.R. Gruen, The genetics of bronchopulmonary dysplasia, *Semin Perinatol* **30** (2006), 185–191.
- [15] A. Hadchouel, F. Decobert, M.L. Franco-Montoya, I. Halphen, P.H. Jarreau, O. Boucherat, E. Martin, A. Benachi, S. Amselem, J. Bourbon, C. Danan and C. Delacourt, Matrix metalloproteinase gene polymorphisms and bronchopulmonary dysplasia: identification of MMP16 as a new player in lung development *PLoS One* **3** (2008), e3188.
- [16] B. Puthothu, M. Krueger, M. Bernhardt and A. Heinzmann, ICAM1 amino-acid variant K469E is associated with paediatric bronchial asthma and elevated sICAM1 levels, *Genes Immun* **7** (2006), 322–326.
- [17] M. Krueger, A. Heinzmann and M. Nauck, Adhesion molecules in pediatric intensive care patients with organ dysfunction syndrome, *Intensive Care Med* **33** (2007), 359–363.
- [18] C. Pieh, M. Krueger, W.A. Lagreze, C. Gimpel, C. Buschbeck, U. Zirrgiebel and H. Agostini, Plasma sE-selectin in premature infants: A possible surrogate marker of retinopathy of prematurity, *Invest Ophthalmol Vis Sci*, (2010) Feb 24. [Epub ahead of print] PubMed PMID: 20181841.
- [19] A. Heinzmann, B. Mailaparambil, N. Mingurilli and M. Krueger, Association of Interleukin-13/-4 and Toll like receptor 10 with preterm births, *Neonatology* **96** (2009), 175–181.
- [20] P.M. Lavoie, C. Pham and K.L. Jang, Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health, *Pediatrics* **122** (2008), 479–485.
- [21] F. Sanger, S. Nicklen and A.R. Coulson, DNA sequencing with chain-terminating inhibitors. 1977, *Biotechnology* **24** (1992), 104–108.
- [22] P.D. Sasiemi, From genotypes to genes, doubling the sample size, *Biometrics* **53** (1997), 1253–1261.
- [23] J. Xu, A. Turner, J. Little, E.R. Bleecker and D.A. Meyers, Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium, hint for genotyping error? *Hum Genet* **111** (2002), 573–574.
- [24] T. Becker and M. Knapp, Maximum-likelihood estimation of haplotype frequencies in nuclear families, *Genet Epidemiol* **27** (2004), 21–32.
- [25] E. Bancalari, Changes in the pathogenesis and prevention of chronic lung disease of prematurity, *Am J Perinatol* **18** (2001), 1–9.
- [26] M.A. Rojas, A. Gonzalez, E. Bancalari, N. Claire, C. Poole and G. Silva-Neto, Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease, *J Pediatr* **126** (1995), 605–610.
- [27] M. Palta, D. Gabbert, M.R. Weinstein and M.E. Peters, Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project, *J Pediatr* **119** (1991), 285–292.
- [28] M.H. Manar, M.R. Brown, T.W. Gauthier and L.A. Brown, Association of glutathione-S-transferase-P1 (GST-P1) polymorphisms with bronchopulmonary dysplasia, *J Perinatol* **24** (2004), 30–35.
- [29] S.N. Kazzi, U.O. Kim, M.W. Quasney and I. Buhimschi, Polymorphism of tumor necrosis factor-alpha and risk and severity of bronchopulmonary dysplasia among very low birth weight infants, *Pediatrics* **114** (2004), 243–248.
- [30] S.S. Strassberg, I.A. Cristea, D. Qian and L.A. Parton, Single nucleotide polymorphisms of tumor necrosis factor-alpha and the susceptibility to bronchopulmonary dysplasia, *Pediatr Pulmonol* **42** (2007), 29–36.
- [31] S.N. Kazzi, G. Tromp, M.W. Quasney and I.A. Buhimschi, Haplotypes of tumor necrosis factor gene and tracheal aspirate fluid levels of tumor necrosis factor-alpha in preterm infants, *Pediatr Res* **64** (2008), 165–170.
- [32] T. Higuchi, N. Seki, S. Kamizono, A. Yamada, A. Kimura, H. Kato and K. Itoh, Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese, *Tissue Antigens* **51** (1998), 605–612.
- [33] B. Puthothu, S. Bierbaum, M.V. Kopp, J. Forster, J. Heinze, M. Weckmann, M. Krueger and A. Heinzmann, Association of TNF-alpha with severe respiratory syncytial virus infection and bronchial asthma, *Pediatr Allergy Immunol* **20** (2009), 157–163.
- [34] M. Chauhan, S. Bombell and W. McGuire, Tumour necrosis factor (-308A) polymorphism in very preterm infants with broncho-pulmonary dysplasia, meta-analysis, *Arch Dis Child Fetal Neonatal Ed* **94** (2009), 257–259.
- [35] B. Thébaud, Angiogenesis in lung development, injury and repair, implications for chronic lung disease of prematurity, *Neonatology* **91** (2007), 291–297.
- [36] T.M. Asikainen, N.S. Waleh, B.K. Schneider, R.I. Clyman and C.W. White, Enhancement of angiogenic effectors through hypoxia-inducible factor in preterm primate lung in vivo, *Am J Physiol Lung Cell Mol Physiol* **291** (2006), 588–595.
- [37] P. Lassus, A. Ristimäki, O. Ylikorkala, L. Viinikka, S. Andersson, Vascular endothelial growth factor in human preterm lung, *Am J Respir Crit Care Med* **159** (1999), 1429–1433.
- [38] C.J. Watson, N.J. Webb, M.J. Bottomley and P.E. Brenchley, Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene, correlation with variation in VEGF protein production, *Cytokine* **12** (2002), 1232–1235.
- [39] A. Stevens, J. Soden, P.E. Brenchley, S. Ralph, D.W. Ray, Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter, *Cancer Res* **63** (2003), 812–816.
- [40] P. Kwinta, M. Bik-Multanowski, Z. Mitkowska, T. Tomasiak, M. Legutko and J.J. Pietrzyk, Genetic risk factors of bronchopulmonary dysplasia, *Pediatr Res* **64** (2008), 682–688.
- [41] R. Lazarus, B.A. Raby, C. Lange, E.K. Silverman, D.J. Kwiatkowski, D. Vercelli, W.J. Klimecki, F.D. Martinez and S.T. Weiss, TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples, *Am J Respir Crit Care Med* **170** (2004), 594–600.
- [42] H.C. Lin, B.H. Su, J.S. Chang, C.M. Hsu, C.H. Tsai and F.J. Tsai, No association of interleukin 4 intron 3 and 590 promoter polymorphisms with bronchopulmonary dysplasia for ventilated preterm infants, *Biol Neonate* **87** (2005), 181–186.
- [43] J. Pavlovic, C. Papagaroufalos, M. Xanthou, W. Liu, R. Fan, N. J. Thomas, I. Apostolidou, E. Papatoma, E. Megaloyianni, S. DiAngelo and J. Floros, Genetic variants of surfactant proteins A, B, C, and D in bronchopulmonary dysplasia, *Dis Markers* **22** (2006), 277–291.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

